The true incidence of obstructive coronary artery disease (CAD) among patients undergoing transcatheter aortic valve implantation (TAVI) is not known Assessment of CAD using angiography only can ...

PALO ALTO, Calif.--(BUSINESS WIRE)--CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced online publication of a study in the American Heart Journal. The paper ...

PALO ALTO, CA--(Marketwired - Mar 10, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the publication of the IMPACT-PCP (Investigation ...

Quest Diagnostics Inc.DGX recently entered into a national specimen-draw agreement with CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics. Per the agreement, both ...

Blood-Based Test Has Potential to Improve Quality of Care and Lower Costs of Evaluation of Obstructive Coronary Artery Disease REDWOOD CITY, Calif. – CardioDx, Inc., a molecular diagnostics company ...

LONDON, UK — Taking a few extra minutes to perform carotid-artery ultrasound alongside stress echocardiography in patients with suspected coronary artery disease (CAD) offers incremental prognostic ...

CardioDx Also Separately Raises $20 Million in New Financing to Support the Company's Commercial Growth and Operations CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular ...